Loading clinical trials...
Loading clinical trials...
A Global Epidemiologic Study to Determine the Prevalence of Neutralizing Antibodies and Related Adaptive Immune Responses to Adeno-Associated Virus (AAV) in Adults With Hemophilia
Conditions
Interventions
Non-treatment, seroprevalence
Locations
23
United States
Orthopaedic Hemophilia Treatment Center
Los Angeles, California, United States
University of Colorado Hemophilia & Thrombosis Center
Aurora, Colorado, United States
Michigan State University
East Lansing, Michigan, United States
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
Medical University of South Carolina (MUSC)
Charleston, South Carolina, United States
Gulf States Hemophilia and Thrombophilia Center
Houston, Texas, United States
Start Date
June 14, 2017
Primary Completion Date
March 17, 2021
Completion Date
March 17, 2021
Last Updated
October 25, 2021
NCT06379789
NCT07226206
NCT05987449
NCT06008938
NCT04645199
NCT07080905
Lead Sponsor
Baxalta now part of Shire
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions